Home/Pipeline/Tolerance-based Immunotherapy Platform

Tolerance-based Immunotherapy Platform

Allergy and Autoimmune Diseases

Pre-clinicalActive

Key Facts

Indication
Allergy and Autoimmune Diseases
Phase
Pre-clinical
Status
Active
Company

About ToleroGenics

ToleroGenics is an early-stage biotechnology company pioneering a curative approach to immune-mediated diseases through its proprietary tolerance-inducing platform. Its core technology combines thermosensitive hydrogels for sustained drug delivery with specialized adjuvants like PLGA nanoparticles and phosphatidylserine (PS)-liposomes to reprogram dendritic cells and boost regulatory T cells (Tregs). The company is seeking investment to advance its pipeline, aiming to overcome the limitations of current allergen-specific immunotherapies (AIT) by offering safer, more effective, and shorter-duration treatments.

View full company profile